A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

Summary

This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory to standard of care therapy or for whom no standard of care options are available. Once the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of single agent LCB02A is determined, the study will proceed to Phase 2 expansion cohorts in selected tumor types.

Timeline

Start

2026-08

Primary completion

2030-02

Completion

2030-08

Drugs

Indications